| Antibody–drug conjugates for cancer therapy A Thomas, BA Teicher, R Hassan The Lancet Oncology 17 (6), e254-e262, 2016 | 638 | 2016 |
| Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline HL Kindler, N Ismaila, SG Armato III, R Bueno, M Hesdorffer, T Jahan, ... Journal of Clinical Oncology 36 (13), 1343-1373, 2018 | 442 | 2018 |
| Refining the treatment of NSCLC according to histological and molecular subtypes A Thomas, SV Liu, DS Subramaniam, G Giaccone Nature reviews Clinical oncology 12 (9), 511-526, 2015 | 333 | 2015 |
| Mesothelin immunotherapy for cancer: ready for prime time? R Hassan, A Thomas, C Alewine, DT Le, EM Jaffee, I Pastan Journal of Clinical Oncology 34 (34), 4171-4179, 2016 | 323 | 2016 |
| Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial A Thomas, A Rajan, A Berman, Y Tomita, C Brzezniak, MJ Lee, S Lee, ... The Lancet Oncology 16 (2), 177-186, 2015 | 318 | 2015 |
| Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression R Hassan, AC Miller, E Sharon, A Thomas, JC Reynolds, A Ling, ... Science translational medicine 5 (208), 208ra147-208ra147, 2013 | 268 | 2013 |
| Targeting topoisomerase I in the era of precision medicine A Thomas, Y Pommier Clinical Cancer Research 25 (22), 6581-6589, 2019 | 261 | 2019 |
| Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial A Lopez-Chavez, A Thomas, A Rajan, M Raffeld, B Morrow, R Kelly, ... Journal of clinical oncology 33 (9), 1000-1007, 2015 | 259 | 2015 |
| Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma R Hassan, HL Kindler, T Jahan, L Bazhenova, M Reck, A Thomas, ... Clinical cancer research 20 (23), 5927-5936, 2014 | 213 | 2014 |
| Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor … R Hassan, E Sharon, A Thomas, J Zhang, A Ling, M Miettinen, ... Cancer 120 (21), 3311-3319, 2014 | 192 | 2014 |
| Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study A Thomas, R Vilimas, C Trindade, R Erwin-Cohen, N Roper, L Xi, ... Journal of Thoracic Oncology 14 (8), 1447-1457, 2019 | 186 | 2019 |
| A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer RJ Kelly, A Thomas, A Rajan, G Chun, A Lopez-Chavez, E Szabo, ... Annals of oncology 24 (10), 2601-2606, 2013 | 174 | 2013 |
| Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial R Hassan, A Thomas, JJ Nemunaitis, MR Patel, J Bennouna, FL Chen, ... JAMA oncology 5 (3), 351-357, 2019 | 170 | 2019 |
| Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors A Thomas, CE Redon, L Sciuto, E Padiernos, J Ji, MJ Lee, A Yuno, S Lee, ... Journal of Clinical Oncology 36 (16), 1594-1602, 2018 | 170 | 2018 |
| Second malignancies after multiple myeloma: from 1960s to 2010s A Thomas, S Mailankody, N Korde, SY Kristinsson, I Turesson, ... Blood, The Journal of the American Society of Hematology 119 (12), 2731-2737, 2012 | 166 | 2012 |
| Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals P Tebas, I Frank, M Lewis, J Quinn, L Zifchak, A Thomas, T Kenney, ... Aids 24 (14), 2187-2192, 2010 | 161 | 2010 |
| Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress A Thomas, N Takahashi, VN Rajapakse, X Zhang, Y Sun, M Ceribelli, ... Cancer Cell 39 (4), 566-579. e7, 2021 | 155 | 2021 |
| Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy R Hassan, B Morrow, A Thomas, T Walsh, MK Lee, S Gulsuner, ... Proceedings of the National Academy of Sciences 116 (18), 9008-9013, 2019 | 153 | 2019 |
| Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies J Murai, A Thomas, M Miettinen, Y Pommier Pharmacology & therapeutics 201, 94-102, 2019 | 143 | 2019 |
| Temozolomide in the era of precision medicine A Thomas, M Tanaka, J Trepel, WC Reinhold, VN Rajapakse, Y Pommier Cancer research 77 (4), 823-826, 2017 | 142 | 2017 |
